Ehave Provides Progress Update on its HPPD Study with University of Melbourne Post published:February 2, 2023 Post category:Press Release
FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder Post published:December 15, 2022 Post category:Press Release
Ehave Shareholder from CEO Ben Kaplan and Corporate Update Post published:December 7, 2022 Post category:Press Release
Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June 10, 2022 Post published:June 3, 2022 Post category:Press Release
Ehave Forms Partnership with Cognitive Apps to Introduce Revolutionary AI Voice Assistant That Will Revolutionize Mental Health in Psychedelic Sector Post published:January 11, 2021 Post category:Press Release
Ehave, Inc. Partners with Cognitive Apps to Add Artificial Intelligence-Powered Mental Health Analytical Platform for Psychedelic Use in G20 Countries Post published:January 7, 2021 Post category:Press Release
Ehave, Inc. Files to List on the Canadian Stock Exchange and Applies to Upgrade to OTCQB Exchange Post published:January 4, 2021 Post category:Press Release
Ehave, Inc. Announces Repositioning of Mycotopia Therapies to Maximize Shareholder Value Post published:December 28, 2020 Post category:Press Release
Ehave KetaDASH Subsidiary Announces Intent to Battle Major Depression through Home Delivery of Ketamine Post published:December 23, 2020 Post category:Press Release
Ehave, Inc. Issues CEO Letter to Stockholders, Reports on Significant Progress and Outlook for 2021 Post published:December 17, 2020 Post category:Press Release